患者の自宅でのケアを含む現実世界の環境における血管起源の慢性潰瘍患者の治療のための同時光磁気刺激 (COMS)、前向き無作為化、対照、評価者盲検、第 IV 相臨床試験 (NAZARÉ)
NAZARÉ:患者の自宅でのケアを含む現実世界の環境における血管起源の慢性潰瘍患者の治療のための同時光磁気刺激(COMS)、ランダム化、対照、評価者盲検、第 IV 相臨床試験
Chronic leg and foot ulcers are defined as wounds that fail to heal in a timely manner, typically persisting for over 4 to 8 weeks without substantial healing despite standard care. These ulcers often result from macro- and microvascular disorders, the most common being chronic venous insufficiency (CVI), alone or with peripheral artery disease (PAD) or microangiopathy. Despite different causes, chronic vascular-origin wounds share similar biological traits and require the same physiological processes for healing.
Vascular issues hinder blood perfusion, reducing oxygen, nutrients, and growth factors, leading to decreased energy metabolism and impaired cell functions necessary for proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Reduced blood supply also limits leukocyte function, compromising the immune response and leading to persistent inflammation and infection. Consequently, these wounds cannot effectively heal, showing prolonged inflammation, persistent infections, and cellular senescence.
Best practice wound care includes compression therapy and physical activity for venous ulcers, and angioplasty, surgery, or bypass for arterial ulcers. These treatments aim to improve blood flow, reduce venous stasis, and enhance venous return. Compression therapy and physical activity lower hydrostatic pressure in the lower limb, while angioplasty and surgery remove arterial blockages or create new blood flow routes.
Recent studies highlight the role of mechano-sensitive (MS) ion channels in skin cell processes and their dysfunction in dermatological disorders. Magnetic stimulation can activate MS TRCP1 channels, enhancing mitochondrial respiration and mitochondriogenesis via the Ca2+/CalModulin(CaM)/NFAT/PGC-1α pathway. Ca2+-activated calmodulin also catalyzes nitric oxide (NO), promoting vasodilation and tissue perfusion.
Bimodal red and near-infrared photobiomodulation can further increase mitochondrial respiration and ATP production by activating Cytochrome C oxidase and mitigating NO-induced downregulation. This synergistic mechanism of concurrent optical and magnetic stimulation (COMS) may amplify Ca2+ and NO-mediated processes like cell proliferation, migration, vasodilation, and angiogenesis while resolving inflammation. Thus, COMS may offer a promising therapy for chronic, inflammation-prone wounds.
The effectiveness of COMS has yet to be validated in large-scale studies. This proposal aims to assess the impact of COMS therapy combined with standard care versus standard care alone on healing, wound closure, recurrence, pain, quality of life, economic outcomes, and device usability in patients with venous leg ulcers (VLU) and VLU associated with PAD in a large-scale multicentric randomized controlled trial.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Background: Chronic leg and foot ulcers are defined as wounds which fail to proceed through phases of wound healing in an orderly and timely manner to produce a durable structural functional and cosmetic closure. Depending on care setting / geographical region, wounds are considered chronic if they persist over more than 4 to 8 weeks with no substantial wound healing under standard of care (SOC) treatment regimen.
Among the most frequent causes for a delayed wound healing process are macro- and microvascular disorders. The most common is a chronic venous insufficiency (CVI), either as standalone or in combination with peripheral artery disease (PAD) or microangiopathy. Despite their differences in etiology, chronic wounds of vascular origin share similar biological features and require promotion of the same physiological processes for wound healing. The vascular constraints reduce blood perfusion and hinder appropriate cellular supply with oxygen, nutrients, and growth factors. This leads to decreased energy metabolism and therefore impaired cellular performance required for cell proliferation, extracellular matrix production, angiogenesis, and tissue regeneration. Additionally, reduced vascular supply decreases the number and ability of leukocytes to engage oxidative bursts, limiting the capacity for efficient pathogen destruction and leading to tissue devitalization. Consequently, the immune response becomes insufficient to deal with the local pathogen load, leading to ongoing inflammation in the wound area. In summary chronic wounds of vascular origins are unable to run through processes of wound healing, showing an inability to respond to local reparative stimuli of the wound environment, prolonged inflammation, persistent infections, and cellular senescence.
Best practice wound care emphasizes the utilization of compression therapy and physical activity for leg ulcers of venous etiology and angioplasty, surgery, or bypass operation for leg ulcers of arterial etiology, both axes of care being guided by the integration of healthcare professionals' clinical expertise with the best available clinical evidence. Compression therapy and physical activity facilitate wound healing by reducing hydrostatic pressure in the lower limb, mitigating venous stasis, and enhancing venous return. To improve the blood supply to the ulcer, angioplasty and surgery aims to clear out a blockage from a leg artery (endarterectomy), while bypass operation aims to put in a new route for blood flow in the leg.
Concurrent Optical and Magnetic Stimulation Recent publications have demonstrated the importance of mechano-sensitive (MS) ion channels in regulating processes such as skin cell proliferation, differentiation and barrier formation and linked their dysfunction to dermatological disorders. Magnetic stimulation has been shown to activate mechanosensitive TRCP1 channels, whereby the resulting ion channel-mediated calcium fluxes stimulate mitochondrial respiration and associated mitochondriogenesis through activation of the Ca2+/CalModulin(CaM) /NFAT/PGC-1α pathway. Ca2+-activated calmodulin has also been shown lead to the catalyzation of nitric oxide (NO), a potent mediator for vasodilation and tissue perfusion.
The concurrent bimodal red and near-infrared photo biomodulation, can further increase mitochondrial respiration and intracellular ATP production through activation of the Cytochrome C oxidase and mitigating its downregulation by increased levels of intracellular NO through its photo dissociation. Through this synergistic mechanism COMS may offer a therapeutic option for amplifying Ca2+ and NO mediated processes such as cell proliferation, migration, vasodilation, and angiogenesis while helping to shift the cytokine profile towards resolution of inflammation. Therefore, COMS may offer a promising therapeutic approach to enable the transition toward healing of therapy refractory wounds that tend to stay in inflammatory phase. The effectiveness of COMS has not yet been tested in a large-scale study. We propose here to assess the impact of COMS therapy+SOC versus SOC only, on healing, wound closure, wound recurrence, pain, quality of life, economic outcomes and device usability, in patients with venous leg ulcers (VLU) and VLU associated with PAD, in a large-scale multicentric randomized controlled trial.
Design: This study is a post market, phase IV clinical trial. A multicentric randomized controlled trial design will be used. 122 consecutive eligible patients with VLU or VLU associated with PAD, cared in outpatient or home settings in Switzerland (6 sites), France (1 site), Germany (2 sites) and Austria (2 sites), will be included and randomly allocated to one of the two study groups. Half of the participants will receive the standard of care (control group) and the other half will receive the standard of care, supplemented with COMS treatment during the 8 first week's post-inclusion (intervention group). Total study duration for each participant will be 24 weeks.
The intervention is single-blinded, i.e. it not blinded to participants and health care professionals but blinded to data assessors. Analysis:
The entire sample (intervention and control groups) will be described, according to the data level, in terms of their demographic and health data, using descriptive statistics. For the analysis of the different outcomes, the proportions or mean values will be compared between control and intervention groups by using classical tests of hypotheses. Additional analyses will be conducted to assess the change of the wound size over time and to compare groups. The statistical software for data science STATA 17.0 SAS version 9.4 or later (SAS Institute Inc., Cary, NC) will be used for data analysis.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究連絡先
研究連絡先
- 名前:Sebastian Probst, Prof. Dr.
- 電話番号:122-558-6563
- メール:sebastian.probst@hesge.ch
研究連絡先のバックアップ
- 名前:Camille Saini, Dr.
- 電話番号:122-558-5274
- メール:camille.saini@hesge.ch
研究場所
-
-
-
Graz、オーストリア
- まだ募集していません
- Medizinische Universität Graz
-
コンタクト:
- Lars-Peter Kamolz, Prof.
- 電話番号:+43 316 385-14685
- メール:lars.kamolz@medunigraz.at
-
Vienna、オーストリア
- まだ募集していません
- Medizinische Universität Wien
-
コンタクト:
- Benedikt Weber, Prof.
- 電話番号:+43 1 40400-77500
- メール:benedikt.weber@meduniwien.ac.at
-
-
-
-
-
Delémont、スイス
- まだ募集していません
- Jura Hospital
-
コンタクト:
- Claudio Ruzza, Dr.
- 電話番号:+41 32 421 27 93
- メール:Claudio.Ruzza@h-ju.ch
-
Kreuzlingen、スイス
- 募集
- Venenklinik Bellevue
-
コンタクト:
- Jürg Traber, Dr.
- 電話番号:+41 71 678 22 66
- メール:j.traber@venenklinik.ch
-
Onex、スイス
- まだ募集していません
- Cité Générations
-
コンタクト:
- Dave Baer, Dr.
- 電話番号:+4122 709 00 00
- メール:dave.baer@cpo.ch
-
Thun、スイス
- まだ募集していません
- Spital Thun
-
コンタクト:
- Thomas Zehnder, Dr.
- 電話番号:+41 58 636 27 44
- メール:Thomas.Zehnder@spitalstsag.ch
-
Zurich、スイス
- まだ募集していません
- University Hospital
-
コンタクト:
- Jürg Hafner, Prof.
- 電話番号:+41 44 255 44 87
- メール:Juerg.hafner@usz.ch
-
-
-
-
-
Essen、ドイツ
- まだ募集していません
- Universitätsklinikum Essen
-
コンタクト:
- Joachim Dissemond, Prof.
- 電話番号:+49 0201 723 36 41
- メール:Joachim.Dissemond@uk-essen.de
-
Hamburg、ドイツ
- まだ募集していません
- University Clinic Hamburg-Eppendorf
-
コンタクト:
- Ewa Stürmer, Prof.
- 電話番号:+49 0201 723 36 41
- メール:Joachim.Dissemond@uk-essen.de
-
-
-
-
-
Malestroit、フランス
- まだ募集していません
- Augustines's Clinic
-
コンタクト:
- Jean-Paul Lembelembe, Dr.
- 電話番号:+33 02 97 73 18 24
- メール:jplembelembe@ghsa.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Age ≥ 18 years Clinical diagnosis of venous leg ulcer (VLU) or VLU with peripheral arterial disease (PAD) Ankle-brachial index (ABI) 0.5-1.3 or ankle pressure > 60 mmHg Ulcer size 2-50 cm² after debridement at screening Ulcer duration > 30 days and < 2 years For patients with diabetes: HbA1c ≤ 12% at screening Able and willing to provide written informed consent prior to study procedures
Exclusion Criteria:
Pregnant or breastfeeding Malignancy in the ulcer area Use of photosensitizing medication within 30 days Severe immunosuppression (including chronic corticosteroid use > 10 mg/day prednisolone equivalent) NYHA class III or IV heart failure End-stage renal disease requiring dialysis Ulcer area reduction > 30% during run-in phase Active infection requiring systemic antibiotics at baseline Use of advanced wound therapies (e.g., negative pressure wound therapy, skin substitutes, hyperbaric oxygen) within 2 weeks prior to screening Participation in another interventional clinical trial within 30 days
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:デバイスの実現可能性
- 割り当て:ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:usual care
Standard of Care treatment will be performed according to a provided standard of care manual according to most recent guidelines followed at each corresponding site (EWMA , S3-Leitlinie,…) and will proceed as follows:
In the case the participant is at home, this procedure will be performed by a caregiver. |
|
|
実験的:COMS Therapy
COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps: Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1) If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device. |
COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps: Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1) If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percent wound area reduction
時間枠:24 weeks
|
Percent wound area reduction (PWAR) at week 12 will be measured from pictures of the wound taken with ImitoWound research application. PWAR is computed as (Wound area at baseline - Wound area at 12 weeks) / Wound area at baseline. The picture of the wound will be taken after dressing removal, wound debridement (if applicable) and wound cleansing. ImitoWound research App will be used in an iPad as instructed in supplier's wound imaging and measurement guidelines. The camera of the iPad will be positioned 20 to 30 cm away from and parallel to the wound. A calibration marker (quick response [QR] code) will be positioned next to and in the same plane of the wound, and a photograph will be taken after recognition of the QR code by the Imito App, automatic wound measurement will take place. Study nurses will receive concise training and a working instruction with step-by-step procedure on how to use Imito App. (See Appendices) Each wound contour will then be checked and confirmed by an expe |
24 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete wound closure
時間枠:24 weeks
|
1) Complete wound closure after 8, 12, 16, 20, 24 weeks. Complete wound closure is defined as complete skin re-epithelialization without drainage confirmed by 2 consecutive trial visits 2 weeks apart |
24 weeks
|
|
Percent Wound Area Reduction (PWAR
時間枠:24 weeks
|
Percent Wound Area Reduction (PWAR) at week 4, 8, 16, 20, 24 will be measured from pictures of the wound taken with ImitoWound |
24 weeks
|
|
Change in Pain assessment
時間枠:24 weeks
|
Change in Pain assessment at week 12 vs. week 0 (VAS Scale). Patient's perception in terms of pain will be assessed using Visual Analog Scale (VAS) from 0 (no pain) to 10 (very strong pain). It will be asked the participant to use this scale to give a measure of general pain perceived prior to any treatment. The use of VAS offers a widespread potential to document the characteristics of disease-related symptoms (Gethin et al. 2014). Such scales are successfully used in the assessment of wound-related symptoms, are inexpensive and easily understood. |
24 weeks
|
|
Change in Wound-QoL
時間枠:24 weeks
|
4) Change in Wound-QoL questionnaire at week 12 vs. week 0 (Wound-QoL). Wound-QoL is a short and easy-to-understand instrument to assess health related quality of life in patients with chronic wounds, especially leg ulcers. It consists of one page 17 Likert scaled items assessing impairments within the preceding seven days. Answers to each item are coded with numbers (0='not at all' to 4='very much'). A Wound-QoL-17 global score on overall disease-specific quality of life is computed by averaging all items. In addition, subscales of the Wound-QoL can be calculated representing different dimensions of disease-specific quality of life by averaging the respective items ("Body": items 1-5, "Psyche": items 6-10 and "Everyday life": items 11-16). Validated translations have been performed in French (France and Switzerland) and German (Germany, Austria and Switzerland). |
24 weeks
|
|
Median time-to-healing
時間枠:24 weeks
|
Median time-to-healing (50, 90, 100%) through up to week 24 |
24 weeks
|
|
Ulcer re-occurrence rate
時間枠:24 weeks
|
Ulcer re-occurrence rate through up to week 24. Recurrence is when a VLU reopens in the same location after healing. |
24 weeks
|
協力者と研究者
協力者
協力者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- NAZARÉ
- PIOMIC (その他の識別子:PIOMIC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Raw data will be shared using Yareta (https://yareta.unige.ch/home) a Swiss research platform using the FAIR priniples
IPD 共有時間枠
from 2027 until 2029
IPD 共有アクセス基準
all researchers
IPD 共有サポート情報タイプ
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。